Home » Zalicus Halts Rheumatoid Arthritis Drug Trial, Stock Plummets
Zalicus Halts Rheumatoid Arthritis Drug Trial, Stock Plummets
The stock of Cambridge biotech Zalicus took a 33 percent dive Monday after the company announced it is stopping trials of Synavive, which it had hoped would improve on drugs now on the market to treat rheumatoid arthritis.
Boston Business Journal
Boston Business Journal
Upcoming Events
-
07May
-
14May
-
30May